Figure 4
GPR157-Gq-IP3 signaling regulates neurogenesis of RGPs.
(A) Plasmid expressing either Gαq-CT (right) or control plasmid (left) was electroporated, together with the GFP-expressing plasmid, into E13 embryos. E15 brain sections were immunostained with antibodies against PAX6 or TBR2. (B) Plasmid expressing either IP3 sponge (right) or control plasmid (left) was electroporated, together with the GFP-expressing plasmid, into E13 embryos. E15 brain sections were immunostained with antibodies against PAX6 or TBR2. (C,D) The graphs show the fraction of GFP-positive cells that were also positive for PAX6 or TBR2 in (A,B) respectively. Data are presented as mean ± s.e.m. (n = 3). *p < 0.05, **p < 0.01. Scale bars: 50 μm. (E) Plasmids expressing GPR157, both GPR157 and Gαq-CT, both GPR157 and IP3 sponge, Gαq-CT, or IP3 sponge were electroporated, together with the GFP-expressing plasmid, into E13 embryos. Cortical cells were prepared, cultured for 3 days and immunostained with antibodies against SOX2 and TUJ1. (F) Plasmids expressing Gαq Q209L or both Gαq Q209L and IP3 sponge were electroporated, together with the GFP-expressing plasmid, into E13 embryos. Cortical cells at 3DIV were immunostained as in (E). (G,H) The graph showing the fraction of GFP-positive cells that were also positive for SOX2 or TUJ1 in (E) and (F) respectively. Data are presented as mean ± s.e.m. (n = 4; more than 100 cells were analyzed in each condition). *p < 0.05, **p < 0.01, ***p < 0.001. Scale bars: 50 μm in (A,B); 20 μm in (E,F).
